Search

Displaying results 5021 - 5030 of 7540 in total
  1. Drug

    Methapyrilene

    go.drugbank.com/drugs/DB04819
    ApprovedWithdrawn

    Methapyrilene, formerly marketed in many drug products, was shown to be a potent carcinogen. Manufacturers voluntarily withdrew methapyriline drug products from the market in May and June 1979.

    Synonyms: N-(α-pyridyl)-N-(α-thenyl)-N',N'-dimethylethylenediamine, N,N-dimethyl-N'-pyrid-2-yl-N'-2-thenylethylenediamineInternational brands: Co-Pyronil
  2. Drug

    Fazpilodemab

    go.drugbank.com/drugs/DB18924
    Investigational

    Fazpilodemab is under investigation in clinical trial NCT04171765 (A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BFKB8488A Compared With Placebo in Participants With Non-alcoholic Steatohepatitis

    Synonyms: Bfkb-8488a (bispecific antibody designed to mimic the metabolic hormone fgf21).
  3. Drug

    Bosakitug

    go.drugbank.com/drugs/DB19101
    Investigational

    Bosakitug (BSI-045B) is under investigation in clinical trial NCT05932654 (POC Study to Evaluate BSI-045B Monotherapy and BSI-045B Add-on Therapy With Dupilumab in Atopic Dermatitis).

  4. Drug

    ATHX-105

    go.drugbank.com/drugs/DB06008
    Investigational

    ATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.

  5. Drug

    Ligelizumab

    go.drugbank.com/drugs/DB11856
    Investigational

    While the precise pathogenesis of CSU is not entirely clear, autoantibodies against IgE receptors, and sometimes against IgE itself, are thought to exist in 30-40% of patients,[A242362,A242367] and the … Similar in mechanism to [omalizumab], another IgE-directed monoclonal antibody, ligelizumab has a distinct binding epitope as compared to its peer (with a small degree of overlap) which appears to confer

  6. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes

  7. Drug

    IMM-101

    go.drugbank.com/drugs/DB15850
    Investigational

    Studies with IMM-101 showed the vaccine’s ability to stimulate cancer patients’ immune systems to help kill cancer cells. … It has shown to be safe and well tolerated to complement conventional cancer therapy for patients with melanoma and pancreatic ductal adenocarcinoma[A220013,A220018,A220023].

  8. Drug

    Zolasartan

    go.drugbank.com/drugs/DB20140
    Experimental

    The usage of the INN stem '-sartan' in the name indicates that Zolasartan is a angiotensin II receptor antagonist, antihypertensive (non-peptidic).

    Categories: Agents Acting on the Renin-Angiotensin System
  9. Drug

    Oftasceine

    go.drugbank.com/drugs/DB11184
    Approved

    Oftasceine is also referred to as Fluorexon. It is used in ophthalmic solutions as a staining agent when fitting soft and hard lenses. It is a fluorescent dye or luminescent agent.

  10. Drug

    Ilacirnon

    go.drugbank.com/drugs/DB16066
    Investigational

    Ilacirnon (CCX-140) is under investigation in clinical trial NCT01440257 (A Study to Evaluate the Effect of CCX140-B on Urinary Albumin Excretion in Subjects With Type 2 Diabetes and Albuminuria).

    Synonyms: 4-Chloro-N-[5-methyl-2-(7H-pyrrolo[2,3-d]pyrimidin-4-ylcarbonyl)-3-pyridinyl]-3-(trifluoromethyl)benzenesulfonamide